IRadimed reported a slight increase in revenue for the first quarter of 2020, with stable net income. The company's cash flow from operations increased, and it maintains a strong balance sheet despite the uncertainty created by COVID-19.
Revenue increased to $8.7 million compared to $8.4 million in Q1 2019.
Net income remained stable at $1.8 million, with EPS of $0.14 per diluted share.
Non-GAAP net income increased to $2.2 million, or $0.18 per diluted share.
Cash flow from operations increased to $1.2 million, and free cash flow was $1.0 million.
Due to the rapidly changing situation and high degree of uncertainty created by the global impact of COVID-19, the Company withdrew its previous guidance on April 7, 2020 and is not providing any additional financial guidance at this time.
Analyze how earnings announcements historically affect stock price performance